Legend Biotech Corp revenue

Legend Biotech Corp's revenue was $1.03bn in fiscal 2025, up 64.0% on the year before. Since fiscal 2018 ($49.1m) it has grown at a compound 54.4% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Legend Biotech Corp: revenue history, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	49	60	75	69	117	285	627	1,029
Growth on the year before	—	+22.1%	+25.0%	−8.2%	+70.0%	+143.7%	+120.0%	+64.0%
Gross profit	—	—	75	69	52	141	411	632
Gross margin	—	—	100.0%	100.0%	44.1%	49.4%	65.5%	61.4%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Legend Biotech Corp	$1.03bn	64.0%	—
Kiniksa Pharmaceuticals International, plc	$946m	58.2%	56.1%
Bridgebio Pharma, Inc.	$946m	167.3%	364.6%
Biocryst Pharmaceuticals Inc	$941m	68.7%	45.3%
Acadia Pharmaceuticals Inc	$1.14bn	11.8%	27.4%
PTC Therapeutics, Inc.	$1.16bn	-35.1%	13.1%

Compare with peers

Head to head: KNSA vs LEGN BBIO vs LEGN BCRX vs LEGN ACAD vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Legend Biotech Corp's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Legend Biotech Corp.